Prostate carcinoma is a highly prevalent biologically and clinically diverse disease,
generally associated with a consistent elevation of prostate-specific antigen levels …

Nonmetastatic castration-resistant prostate cancer (nmCRPC)-defined as prostate-specific
antigen (PSA)> 2 ng/mL, testosterone castration levels< 1.7 nm/L, and the absence of …

Introduction The emergence of novel hormonal therapies and the increase availability of
sensitive next-generation imaging techniques has significantly changed the management of …

Prostate cancer remains a significant cause of cancer-related deaths in men in the United
States. Significant advances in the treatment of metastatic castration-resistant prostate …

Patients with nonmetastatic castration-resistant prostate cancer (CRPC) are a
heterogeneous population with regard to risk of progression to metastatic disease …

ABSTRACT Introduction: Prostate cancer (PCa) is currently the second most common
cancer affecting men worldwide. Metastatic castration-resistant prostate cancer (mCRPC) is …

Background: Prostate cancer is one of the most common cancers in men in US and
European countries. Despite having a favorable prognosis, the incidence of incurable …

Lately the development of 3 novel second-generation androgen receptor antagonists
(enzalutamide, apalutamide, and darolutamide) chanced the treatment landscape of …

Most of the updates in the 2015 NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines) for Prostate Cancer center on the systemic therapy front, with a host of newer …

Prostate cancer (PCa) continues to be one of the leading causes of cancer-related deaths in
men worldwide (1). Localized PCa responds well with the initial treatment such as surgery …